Clinical Trials Logo

Retroperitoneal Fibrosis clinical trials

View clinical trials related to Retroperitoneal Fibrosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06065852 Recruiting - Fabry Disease Clinical Trials

National Registry of Rare Kidney Diseases

RaDaR
Start date: November 6, 2009
Phase:
Study type: Observational [Patient Registry]

The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research. The purpose of this research is to: - Develop Clinical Guidelines for specific rare kidney diseases. These are written recommendations on how to diagnose and treat a medical condition. - Audit treatments and outcomes. An audit makes checks to see if what should be done is being done and asks if it could be done better. - Further the development of future treatments. Participants will be invited to participate on clinical trials and other studies. The registry has the capacity to feedback relevant information to patients and in conjunction with Patient Knows Best (Home - Patients Know Best), allows patients to provide information themselves, including their own reported quality of life and outcome measures.

NCT ID: NCT05428826 Recruiting - Clinical trials for Idiopathic Retroperitoneal Fibrosis

Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis

METRO
Start date: November 25, 2022
Phase: Phase 4
Study type: Interventional

Adult patients with a diagnosis of idiopathic retroperitoneal fibrosis Prospective multicentric cohort study Intervention : administration of prednisone during 9 to 21 months at 1mg/kg/day at inclusion.

NCT ID: NCT04762810 Recruiting - Clinical trials for Idiopathic Retroperitoneal Fibrosis

A Prospective Study of Cyclophosphamide Treatment for Idiopathic Retroperitoneal Fibrosis

IRPF
Start date: January 3, 2020
Phase: Phase 4
Study type: Interventional

This prospective, interventional, controlled study is aimed to evaluate the efficacy and safety of cyclophosphamide in the treatment of idiopathic retroperitoneal fibrosis, which refers to the chronic nonspecific inflammation of retroperitoneal fascia and adipose tissue that gradually evolves into fibroproliferative disease.

NCT ID: NCT04762784 Recruiting - Clinical trials for Idiopathic Retroperitoneal Fibrosis

A Prospective Study of Tocilizumab in the Treatment of Idiopathic Retroperitoneal Fibrosis

Start date: July 1, 2020
Phase: Phase 4
Study type: Interventional

This is a prospective study to investigate the treatment response of Tocilizumab on patients with idiopathic retroperitoneal fibrosis(IRPF). Methods: All the patients fulfilling diagnostic criteria of IRPF would be enrolled. The IRPF patients will accept Tocilizumab or Glucocorticoid monotherapy for 3 months. Endpoints: The primary endpoint is to investigate the response of Tocilizumab on IRPF patients; the secondary endpoints include the decrease of inflammatory markers, side effect.

NCT ID: NCT04314323 Recruiting - Clinical trials for Idiopathic Retroperitoneal Fibrosis

National Registry of IRPF in China

Start date: March 17, 2020
Phase:
Study type: Observational

The aim of this study is to establish a nation-wide cohort study of idiopathic retroperitoneal fibrosis (IRPF) in China. Methods: All the patients fulfilling diagnostic criteria of IRPF would be enrolled from multi-centers around China. A online database system has been established. Endpoints: The primary endpoint is to investigate the clinical manifestations of Chinese IRPF patients; the secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.

NCT ID: NCT04312854 Recruiting - Clinical trials for Idiopathic Retroperitoneal Fibrosis

A Prospective Cohort Study of IRPF in China

IRPF
Start date: January 17, 2020
Phase:
Study type: Observational [Patient Registry]

This is a cohort study to investigate the disease course and treatment response of patients with idiopathic retroperitoneal fibrosis(IRPF). Methods: All the patients fulfilling diagnostic criteria of IRPF would be enrolled around China. A online database system will been established. Endpoints: The primary endpoint is to investigate the clinical manifestations of Chinese IRPF patients; the secondary endpoints including the demographic features,laboratory characteristics, immunological tests, imaging and pathological features, in addition, the treatment and prognosis of the disease.

NCT ID: NCT04047576 Recruiting - Clinical trials for Retroperitoneal Fibrosis

Study of Sirolimus in Idiopathic Retroperitoneal Fibrosis

Start date: July 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Retroperitoneal fibrosis refers to a group of diseases characterized by hyperplasia of the fibrosclerotic tissues in the retroperitoneal space, which can compress the surrounding ureters and inferior vena cava and cause serious complications such as aortic aneurysm, renal failure, and even death. The lesion is diffuse and difficult to resect. corticosteroid is the first-line medication, but the recurrence rate of the disease is high, especially after dose reduction of corticosteroid. Therefore, the combined use of immunosuppressants is very important in preventing disease recurrence and reducing the toxic and side effects of long-term corticosteroid. Sirolimus plays dual roles in inhibiting lymphocyte activation and fibroblast proliferation. It is inferred from its mechanism that sirolimus is a good potential treatment option for idiopathic retroperitoneal fibrosis. Therefore, we conducted this RCT on patients with idiopathic retroperitoneal fibrosis to determine the efficacy and safety of sirolimus.

NCT ID: NCT03133949 Recruiting - Clinical trials for Retroperitoneal Fibrosis

Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria

Start date: July 8, 2010
Phase: N/A
Study type: Observational

Inflammatory aortitis probably represents a heterogeneous group, and the clinical experience accumulated over the last ten years, shared by the experts of the subject, is that the initial clinical, biological or radiological characteristics should make it possible to differentiate them and dismember the Nosological field. This will be an essential first step before studying prognosis, risk factors, and therapeutic options. The search for diagnostic criteria on a large series, similar to the study of classification of vascularites of the ACR in 1990, should make it possible to homogenize the diagnoses for the different teams working on the subject, and to begin work Collaborations, which alone can improve patient care in the future.

NCT ID: NCT01240850 Recruiting - Clinical trials for Idiopathic Retroperitoneal Fibrosis

Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial

FIPREDEX
Start date: May 2007
Phase: Phase 3
Study type: Interventional

Chronic periaortitis is a clinico-pathological entity encompassing idiopathic retroperitoneal fibrosis and perianeurysmal retroperitoneal fibrosis. The treatment of this disease is generally based on the use of glucocorticoids, which are often effective. However, prolonged steroid treatments are usually needed to achieve a sustained remission; additionally, patients frequently develop disease relapses following treatment discontinuation, therefore they may be exposed to high cumulative doses of glucocorticoids. Preliminary data reported in the literature show that methotrexate may be effective in combination with prednisone for retroperitoneal fibrosis. In addition, methotrexate is often used as a steroid-sparing agent in different inflammatory diseases. The aim of this study is to evaluate whether a treatment with low-dose prednisone plus methotrexate is non-inferior to conventional dose-prednisone in achieving remission in retroperitoneal fibrosis patients.